Technical Analysis for KROS - Keros Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 38.58 -1.20% -0.47
KROS closed down 1.2 percent on Friday, August 14, 2020, on 24 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Up Up
Historical KROS trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Walk Strength -1.20%
Wide Bands Range Expansion -1.20%
Above Upper BB Strength -1.20%
Overbought Stochastic Strength -1.20%
Upper Bollinger Band Touch Strength -1.20%
Stochastic Sell Signal Bearish 7.14%
Upper Bollinger Band Walk Strength 7.14%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Biopharmaceutical Organ Systems Rare Diseases Disorders Pulmonary Arterial Hypertension Anemia Myelodysplastic Syndrome Hematology Genodermatoses Osteoporosis Myelodysplastic Syndromes Myelofibrosis Blood Disorders Hematopathology Thrombocytopenia

Is KROS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 42.26
52 Week Low 24.5
Average Volume 120,220
200-Day Moving Average 0.00
50-Day Moving Average 34.16
20-Day Moving Average 32.68
10-Day Moving Average 35.87
Average True Range 3.11
ADX 24.61
+DI 21.38
-DI 8.72
Chandelier Exit (Long, 3 ATRs ) 30.59
Chandelier Exit (Short, 3 ATRs ) 35.05
Upper Bollinger Band 39.93
Lower Bollinger Band 25.43
Percent B (%b) 0.91
BandWidth 44.38
MACD Line 1.46
MACD Signal Line 0.62
MACD Histogram 0.8431
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 41.06
Resistance 3 (R3) 40.97 40.06 40.65
Resistance 2 (R2) 40.06 39.43 40.11 40.51
Resistance 1 (R1) 39.32 39.04 38.87 39.41 40.37
Pivot Point 38.41 38.41 38.18 38.45 38.41
Support 1 (S1) 37.67 37.78 37.21 37.75 36.79
Support 2 (S2) 36.76 37.39 36.80 36.65
Support 3 (S3) 36.01 36.76 36.51
Support 4 (S4) 36.10